secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001171843-24-006086
Event type: earnings
Sentiment:  negative
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q3 revenue falls 13% to $22M; net loss widens to $4.8M
-------------------------------------------------------------------------

- Revenue $22.0M, down 13.4% YoY from $25.4M; gross margin stable at 58.1%.
- GAAP net loss $4.8M (($0.11)/diluted share) vs $1.2M loss a year ago; included $1.2M non-cash pension settlement charge.
- Adjusted EBITDA $1.3M (6.0% margin) vs $2.2M (8.9%) prior year; nine-month adjusted EBITDA $4.2M vs $10.9M.
- Operations used $0.8M cash in Q3 vs $4.4M generated last year; revolving credit facility constrained by net leverage ratio.
- CEO cites challenging market; expects $1M quarterly cost savings from additional actions starting Q4; new products gaining adoption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324006086/0001171843-24-006086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324006086/f8k_110724.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer